Treatment-seeking behavior and practices among caregivers of children <5 years with presumed malaria in rural Uganda

Yang Jae Leea\*, Gautam Adusumillia, Rauben Kazungub,Godwin Anywarb, Francis Kyakulagac, Esther Katuurab, Shanti Parikhd, Merlin Willcoxe

aSchool of Medicine, Washington University in St. Louis, USA;

bDepartment of Plant Sciences, Microbiology & Biotechnology Makerere University, Kampala, Uganda; cMinistry of Health, Uganda, Namutumba District;

dDepartment of Anthropology, Washington University in St. Louis, USA;

eDepartment of Primary Care and Population Sciences, University of Southampton, UK

\*Corresponding author: Tel: +1 706 691 9813; E-mail: jaelee@wustl.edu

**Abstract**

**Background**

We aimed to determine the rate of herbal medicine usage and the treatment-seeking patterns of children under 5 years of age with presumed or confirmed malaria in in an endemic area of Uganda.

**Methods**

We interviewed guardians of 722 children aged 6 months to 5 years, who had experienced an episode of presumed malaria in the previous 3 months, about the illness history.

**Results**

36.1% of patients took herbal medicine but most also soughtmodern medical care. Overall, 79.2% received Artemether-Lumefantrine (AL), but 42.7% received the correct AL dose. Of the 36.6% of patients treated in drug shops, 9.8% had a diagnostic test and 30.2% received the correct dose of AL. Antibiotics were provided with AL often at drug shops (62%) and formal health centers (45%). There were no significant differences in the self-reported outcomes associated with different treatments.

**Conclusion**

Almost all patients who took herbal medicine also took modern antimalarials, so further research is needed to explore potential interactions between these. . Although formal health facilities provide correct diagnosis and dose of AL to a majority of children with malaria, many children still received inappropriate antibiotics. Quality of care was worse in drug shops than in formal health facilities. .

[200 words]

**Key words:** Artemisinins, Guideline adherence, Health care seeking behaviour, Herbal medicine, Malaria, Uganda**Introduction**

The World Health Organization (WHO) estimates that globally, there were 214 million cases of malaria in 2015 and 438,000 deaths, most of these in Sub-Saharan African children (1). Malaria is an important contributor to continued poverty because it adversely affects economic growth (2). However, in Uganda, intensive efforts at malaria control in the last decade have contributed to meeting the Millenium Development Goal target on reduction of child mortality: the overall under-5 child mortality rate declined from 116 per 1000 (in 2002-2006) to 64 per 1000 in 2012-2016 (3).

In the 1990s, resistance to chloroquine and sulfadoxine-pyrimethamine resulted in a great increase of mortality and morbidity from malaria (4). The WHO recommended that ACTs be used as first-line treatments for *P. falciparum* in all malaria endemic countries (5). Uganda adopted Artemether-Lumefantrine (AL), sold as Coartem, as the first-line treatment for malaria in 2004, and it is still regarded as the national gold standard (6). Artemisinin derivatives clear parasitemia more rapidly than all other currently available drugs. Recent increases in the use of ACTs along with public health interventions, such as the increased use of insecticide-treated bed nets, have greatly reduced the global burden of malaria (1, 7).

However, in 2014-2016, the incidence of malaria increased slightly in most of the world, and malaria deaths stalled (1). The reasons for this are unclear. Artemisinin resistant *P. falciparum* has emerged in Asia (8, 9), and in 2017, a case study reported artemisinin resistance in Equatorial Guinea (10). Early detection of artemisinin resistance in Sub-Saharan Africa will be important in forming policy for malaria containment. Further, investigating the quality of malaria case management at the household and health center levels is critical.

In Uganda, public health facilities offer free services to patients. However, these health facilities frequently suffer from stock-outs of medicine and diagnostic equipment, which leads to patients frequenting drug shops often staffed by underqualifed or unlicensed personnel operating with very little to no oversight or compliance with guidelines (11, 12). The national policy recommends a “test and treat” strategy for malaria (13), but this is not always implemented, especially in drug shops.

To compensate for lack of access to western medicine, herbal remedies are often used to treat malaria and other illnesses. For example, one study in western Uganda, in Kasese district found that 81% of respondents had used herbal medicine at some point in their lives (14). In areas where medical personnel and drugs are insufficient to treat illnesses, the World Health Organization recommends the implementation of traditional / herbal medicines including medicinal plants as a form of healthcare, and Uganda supports the use of herbal medicine if proven effective towards its integration (15). The primary outcome of the study was the rate of herbal medicine usage. Secondary outcomes were undertaken to determine the prevalence of use of different treatments for malaria sought by caregivers of under-5 children, the diagnostic and prescription practices of healthcare workers in Uganda, as well as associated outcomes. Given its observational nature, the portion of this study regarding outcomes associated with various types of medicine was intended as an exploratory study with the necessity of further research to confirm the findings.

# Methods

We conducted a cross-sectional survey of caregivers of children presumed to have had malaria in the past three months in eastern Uganda. We used a “retrospective treatment outcome” (RTO) method, which has previously been successfully used in Mali to identify treatment-seeking patterns and to generate hypotheses about the effectiveness of different treatments (16-18).

**Study area and period**

This study was conducted in thirty villages in Namutumba district, Eastern Uganda in June 2015, at the end of the rainy season which lasted from March to June. Namutumba district was chosen because of its high poverty levels and high prevalence of malaria due to the presence of marshland. The 2014-2015 malaria survey found that 49% of children were RDT positive for malaria in this region (19). Up to 90% of the 268,900 inhabitants of Namutumba live in rural areas, while 10% live in semi-urban parts of the district. There is only one paved road through the district.

**Study population**

This study recruited participants with sub-county stratification adjusted for population in Namutumba district. Respondents were caregivers of children between six months and five years of age who had had one or more signs and symptoms of malaria in the past three months. Children under six months were excluded because other causes of fever are more common than malaria in this age group (20, 21). We anticipated that many children would not have been tested for malaria, so as well as asking about diagnostic tests, we asked questions about symptoms.

**Questionnaire for caregivers**

A structured questionnaire was administered to the respondents. Demographic information was collected to ensure that the respondents met the inclusion criteria. We asked specific questions to define the disease.We asked whether health care was sought, whether a diagnostic method was used, within which time-frame, which treatments were taken, and the duration of the illness. We also asked about outcomes associated with each treatment. We asked whether the child developed symptoms of severe malaria, such as becoming lethargic, unresponsive, showing symptoms of jaundice, and having convulsions.

If the plants used as local remedies were unfamiliar to the research team, the respondents were asked to show the plant used. Specimens of each plant species were collected for formal botanical identification at the Makerere University Herbarium. The scientific names of the plant species were validated based on the Kew database (22). Plant families were verified using the Angiosperm Phylogeny Group III at <http://www.mobot.org/MOBOT/research/APweb/>.

**Sample size and sampling procedure**

The sample size calculation was based on a two-stage cluster design, with villages constituting the primary units (clusters) and households the secondary units (samples) (23, 24). The following estimations were used in calculating the desired sample size: estimated proportion of patients using herbal medicine = 20%; standard error = 0.025; design effect = 2; clusters required = 30; N total required = 525. Prevalence of use of herbal medicine was the primary outcome. Through random sampling stratified by the population of each of the seven sub-counties of Namutumba District, thirty rural villages were selected.

**Data collection method and tools**

The questionnaires were administered by eight university graduates fluent in English and Lusoga, chosen through an application review and subsequent interviews. Six were health workers in Namutumba District who contributed their knowledge of the district to streamline participant interviews. Each data collector was trained on the use of the questionnaire, explaining the purpose of the study to the respondents, and taking written consent from the caregiversof the children. The structured questionnaire was initially prepared in English, translated to Lusoga, and checked for its consistency through back translation to English.

Village Health Team (VHT) volunteers, who are elected by the village to serve as community health workers, were present at every survey to build trust and rapport. Each team of two to three data collectors administered structured surveys in one study site per day. If there were several cases of presumed malaria in the same household, only the latest case was recorded. The supervision team planned to repeat 10% of the interviews at random, at least one from each of the 30 study sites, to control the quality of the data collection. When multiple discrepancies arose between the information collected by the data collection team and the supervision team, the surveys of the data collector on that day were all excluded.

To ensure the greatest probability that the children had malaria and not other febrile illnesses, questions on rapid diagnostic tests were asked, and those that tested negative were excluded. We excluded cases with symptoms most likely caused by an illness other than malaria (for example, rashes all over the body or swollen body or legs).

**Quantitative Data analysis**

Data was first checked for completeness and then entered into Epi-Info version 7. After data entry and cleaning, the data was transferred to Microsoft Excel 2013 for analysis. Proportion-based analyses were conducted to evaluate treatment outcomes based on drug combinations, order of medication usage, appropriate vs. inappropriate dosages, and clinical diagnosis status. Similar analyses were conducted to evaluate differences in respondents who visited formal and informal drug shops. We also tested whether there were correlations between treatments and reported outcomes, specifically whether the patient considered themselves to be “cured” (i.e. to have no more symptoms).The Z-test for two population proportions was used to test for significance of proportional differences (25).

**Ethical issues**

Verbal prior informed consent was obtained from all local council chairmen of the thirty study sites before data collection. The purpose of the study was explained in the local language (Lusoga) to study participants and written consent was obtained, before each interview commenced. Personal information was kept confidential and available only to the study team. The interviews took place at a time and place of the participants’ choice. All data from the interviews were stored in a password-protected laptop, and all paper copies were kept in a locked cabinet.

The study received ethical clearance from Washington University in St. Louis Institutional Review Board, The AIDS Support Organization (TASO) Institutional Review Board in Uganda, and Uganda National Council of Science and Technology (UNCST) (HS 1816).

# Results

**Subject Demographics**

Cluster size depended on the local prevalence of malaria and the size of the village, but we interviewed an average of 24 caregivers per village. We interviewed a total of 752 caregivers of children with presumed malaria. Of these, 30 were excluded because of data discrepencies between the collection and supervision teams, so 722 cases were retained. The mean age of the 722 children surveyed was 28 months and 54.7% were boys. The characteristics of participants showed that they were representative of the population of Namutumba District: 74.3% of households reported an average monthly income below $14 per month, and 95.1% of respondents were subsistence farmers –.

**Treatment-seeking**

Most respondents assessed (646/722, 89.5%) eventually sought treatment at a public health facility and 219 (30.5%) did so within the first 24 hours. Sixteen respondents (2.2%) exclusively used herbal medicines at home and did not take any other treatment. The remaining 706 patients obtained modern medicines. Out of the 706 patients that took modern medicine, 245 also used herbal medicine. Overall, 261 of the 722 respondents (36.1%) reported using herbal medicine. All herbal medicine was given at home, independent of drug shops and health centers. By far the most commonly used plant was *Vernonia amygadalina* (92.0%, 240/261). The second commonest was *Chenopodium opulifolium* (31 respondents). Several other plants were also commonly used, and in total 51 plant species were reported for the treatment of malaria (Table 3). Whereas *V. amygdalina* was often prepared alone, many of the other plants were prepared in a mixture with *V. amygdalina*. The number of plant species in each remedy ranged from one to seven (median = 2). Many herbs were prepared through squeezing the leaves or as a decoction, and the practice of preparation for herbal remedies seemed to be similar across households. Most herbal remedies were taken orally, although there were several that were taken through a bath of the solution.

The majority of respondents (422/722, 58%) consulted a formal health care facility, but a large proportion (39.3%) bought medicines from a drug shop. Only 9.2% of patients who went to drug shops had a diagnostic test, compared to 72.0% (304/422) of those who consulted a formal health facility (table 1). In some cases, these treatments overlapped and resulted in drug combinations, but in most cases the drug combinations were received at the same time from one location. For the purpose of this analysis, all of these were grouped together and stratified by location of each prescription, irrespective of order.

Formal health facilities prescribed a significantly higher proportion of AL among the total prescriptions reported than drug shops (p=0.00001). For both formal health centers and informal drug shops, 203 of 376 (54.0%) total AL prescriptions were of an appropriate or excessive dose. Underdosing was reported in 173 of 376 (46.0%) cases. Of the 376 cases given AL, 148 (39%) also received co-trimoxazole, and other patients received a variety of other treatments (table 2). Notably, in a sub-analysis of drug combinations, drug shops provided antibiotics including CTX along with AL 62% of the time whereas formal health centers did so 45% of the time. Both findings are notable for potential overprescription to treat malaria-like symptoms.

Many respondents (247) were excluded from a more detailed analysis because either their illness started less than seven days before the survey, thus rendering the symptom clearance rate irrelevant, or because the patients forgot the exact treatments that they took. Out of the 475 respondents for which a more detailed analysis was possible, eleven exclusively took herbal medicine and 19 took herbal medicine and then afterwards took modern non-antimalarials.

The vast majority of patients who took herbal medicine (156/184, 84.8%) started it on the first day of their symptoms and took it as their first treatment. However most of these patients (131/156, 84.0%) then took a modern medicine, most often an antimalarial, within the next three days. Additionally, higher househould income (p=0.01), access to motorized transport (p=0.005), and higher health center level nearest to residence (p=0.001) were correlated with shorter length of illness. **Outcomes associated with different treatments**

The mean duration of illness after treatment (MDIT) as defined by becoming afebrile in those who took any antimalarials was 8.01 days compared to 7.65 in those who took no antimalarial (table 2). The fever clearance rate was similar in both groups (98.6% in antimalarial vs. 97.6% in those that did not take an anti-malarial medicine, but took only herbals and / or a non-antimalarial). None of the differences in duration of illness after treatment or fever clearance rate were found to be significant in this analysis, even in patients with a confirmed malaria diagnosis (table 2). Under or over-dosage of AL was not associated with any significant differences in self-reported duration of illness or fever clearance rates. Addition of co-trimoxazole to AL (at a correct or excessive dose) appeared to be associated with a higher self-reported fever clearance rate at day 3 than AL alone, but these differences disappeared from day 7 onwards (data not shown). It is impossible to evaluate outcomes associated with different herbal remedies, because most patients who took herbal medicines started a modern antimalarial soon afterwards.

# Discussion

**Summary of main findings**

Although about one-third of patients in this study took herbal medicine as their first treatment, the vast majority then sought modern medical care. The majority went to formal health facilities and received AL; a diagnostic test was done to confirm malaria in about ¾ of cases, but only about half of patients received the recommended dose of AL. Formal health facilities frequently suffer from medicine stock-outs (11), perhaps leading the medical care providers to give less than the recommended dose of AL.Over one-third of patients were treated in drug shops, where very few had a diagnostic test (9.2%) or received the correct dose of AL (30.2%). Thirty-eight percent of patients received Co-trimoxazole, in most cases together with AL. At day 7, only 74% of patients who had taken AL had total symptom clearance. However, there were no significant differences in the self-reported outcomes associated with a variety of different treatments, suggesting that some of the patients may not actually have had malaria.

**Strengths and limitations**

This was a cross-sectional retrospective survey of the community using a sampling technique to ensure that respondents were likely to be representative of this community. In addition we conducted quality control measures. As the survey was retrospective, not all cases of malaria were confirmed, but as it was conducted at the end of the malaria season in an endemic area and we used the exclusion criteria detailed in the methods, it is likely that the majority of cases really did have malaria. We did a sensitivity analysis including only those patients with a positive malaria test, and the results remained the same. It was not possible to confirm “cure” through blood tests, so the outcomes are purely based on reporting of the duration of symptoms by the parents of the patients. Use of patients’ reported length of illness to calculate “mean duration of illness after treatment” and fever clearance rate as defined by the termination of a fever on specific days after treatment is more useful than simply asking about “cure” versus “no change or worse” after taking a specified treatment (which was done in previous similar studies) (26).

In a retrospective study, recall bias could negatively affect the reliability of the data collected, although we attempted to minimize this by limiting our parameters to children ill in the last three months. To minimize the impact of low literacy in our study population in the integrity of our data, we inspected the respondents’ prescription books to find what medicine that they were prescribed. Selection bias probably explains the lack of difference in symptom duration between patients who took AL and those who did not: in the group which had no malaria test, it is likely that a proportion of the patients did not actually have malaria. In the group with a positive malaria test, those with more serious illness were probably more likely to receive AL.

The fact that most of the interviewers were health workers, and that the interviews were observed by volunteer community health workers, may have influenced the responses of participants (making them less likely to report exclusive use of herbal medicines, for which they might fear criticism from health workers, and more likely to report use of the recommended antimalarial). As the reported exclusive use of herbal medicine was lower than anticipated, the sample size was insufficient to look at differences in outcomes associated with different herbal medicines.

**Comparison with existing literature**

Reported rates of AL use were higher than in many African countries (1), but the fever clearance rate at day 7 was lower than expected in patients having taken AL. There is no evidence that artemisinin resistance has reached Uganda – only a single case has been reported in Africa (10). The lower than expected fever clearance rates at day 7 are probably explained by persistence of other symptoms or illnesses which are not related to malaria.

The low exclusive use of herbal medicines may be testimony to the success of public health education campaigns on rapid treatment-seeking for childhood fevers. Our results confirm that *Vernonia amygdalina* is the most popular antimalarial plant in Uganda, as reported by several other studies (27, 28). However a clinical trial has shown that (at least when given alone) a decoction is only moderately effective (14). Our study shows that individuals who took herbal medicine by itself or with non-malarials had a relatively high fever clearance rate of 72.9% by day 7, perhaps because some herbal medicines are effective, or because some of these patients may not actually have had malaria since herbals are often taken at home without a diagnostic test, or because some may already have acquired a degree of immunity to malaria. Uganda being a malaria endemic nation, it has been observed that many people can maintain parasitemia without experiencing symptoms (29). What is interesting in this study is that the leaves were mainly prepared as a fresh juice (as opposed to a decoction which is more common in other areas (28)) and that it was very often combined with a variety of other plants, especially *Chenopodium opulifolium*and *Ocimum americanum* L.  It would be worth investigating these different preparations and combinations, which may lead to synergistic effects (30).

**Implications for policy, practice, and further research**

The most concerning finding from our study is that a large number of patients first seek care from drug shops, which often provide inadequate quality of care (inadequate diagnosis, and inadequate treatment dose). The high level of antibiotic use is potentially harmful both because of increasing the risk of antibiotic resistance, and because of the risk of serious side-effects such as Stevens-Johnson syndrome. Although some antibiotics like CTX has weak antimalarial properties, it is not recommended for the treatment of malaria, but it is the first-line drug in Uganda for pneumonia (6). Further research is needed to understand the reasons for the high levels of antibiotic prescripton in Uganda, in patients with presumed (or confirmed) malaria.

# Conclusion

Management of malaria in Uganda has improved since previous surveys, and formal health facilities are now providing correct diagnosis and treatment to a majority of children with malaria – although there still remains some room for improvement. However, a very high proportion of patients was also given an antibiotic (most commonly co-trimoxazole). More action is needed to reduce the over-prescription of CTX in patients with malaria, and to improve the quality of care, especially that given by drug shops. Although 36% of patients took a herbal medicine, only 2.2% took it alone, without any modern antimalarials. Further research is needed on potential interactions of herbal medicines with modern antimalarials.

## Authors’ contributions

YJL, SP, and ML conceived the study; YJL, SP, FK, and ML designed the study protocol; YJL and KR carried out and supervised the study; YJL, GA, KR, and ML conducted data analysis; YJL annd KR conducted data entry; YJL, GA, and ML drafted the manuscript; GA, EK, KR, and SP critically revised the manuscript for intellectual content. All authors read and approved the final manuscript. YJL and ML are gurantors of the paper.

|  |  |
| --- | --- |
| Name | Role in project |
| Mr. Yang Jae Lee | Principal Investigator. Protocol design and study planning. Supervisor of fieldwork. Leader of ethnobotanical survey and supervisor of data collection. Quality control of data entry. In charge of data analysis and preparation of manuscript. Financial manager for the project. |
| Mr. Francis Kyakulaga | Logistical planning Namutumba district. Took part in supervising data collection and entry. |
| Mr. Godwin Anywar, MSc, Ph.D candidate | Botanical identification of voucher specimens. Took part in supervising data collection. Preparation of the manuscript |
| Dr. Esther Katuura, MSc, Ph.D | Quality control of data entry. Took part in development of protocol. |
| Dr. Merlin Willcox, BM BCh, D.Phil, MRCGP | Protocol design, advice on implementation of the study, revision of the manuscript |
| Dr. Shanti Parikh, Ph.D | Took part in the development of protocol |
| Mr. Rauben Kazungu, BSC. | Supervisor of quality analysis. Data entry and data analysis |
| Mr. Gautam Adusumilli | Preparation and revision of the manuscript, literature review |

## Acknowledgements

This project would not have been possible without the hard work and contributions in the field from research assistants Peter Okuku, Kasubi Wycliffe, Booto Agrey, Busense Patrick, Kasada Eric, Kaigwa Godfrey, and Baligeya Moses. We owe the inhabitants of villages and towns across Namutumba district for their willing participation in the research study and for their hospitality and warmth. We would also like to thank the 60 community health workers who facilitated the interviews and data collection, as well as the 30 village chairpersons who gave us formal consent to conduct our study and who gave us vauable information on the villages. Also, the district health leadership of Namutumba district was very accommodating and helpful. We would also like to thank Professor Sukkoo Kim for his guidance in statistical analysis.

## Funding

We are very grateful for the financial assistance of the Office of Undergraduate Research at Washington University in St. Louis through the Summer Undergraduate Research Award and through the 2015 W.H.R. Rivers Summer Research award.

## Competing interests

The authors declare that they do not have any competing interests.

## Ethics approval and consent to partcipate

Verbal prior informed consent was obtained from all local council chairmen of the thirty study sites before data collection. The purpose of the study was explained in the local language (Lusoga) to study participants and written consent was obtained, before each interview commenced. Personal information was kept confidential. The interview teams promised to keep the personal information confidential. The interviews took place at a time and place of the participants’ choice. All data from the interviews were stored in a password-protected laptop, and all paper copies were kept in a locked cabinet.

The study received ethical clearance from Washington University in St. Louis Institutional Review Board, The AIDS Support Organization (TASO) Institutional Review Board in Uganda, and Uganda National Council of Science and Technology (UNCST) (HS 1816).

# References

1. WHO. *World Malaria Report 2017.* Geneva: World Health Organisation, 2018.

2. Gallup JL, Sachs JD; The economic burden of malaria. *Am J Trop Med Hyg* 2001;**64**(1-2 Suppl):85-96.

3. Republic of Uganda; The Uganda Malaria Reduction Strategic Plan 2014–2020. Kampala: Malaria Control Programme, Ministry of Health, 2015.

4. Trape JF, Pison G, Preziosi MP, et al.; Impact of chloroquine resistance on malaria mortality. *C R Acad Sci III* 1998;**321**(8):689-97.

5. WHO. *Guidelines for the treatment of malaria. WHO/HTM/MAL/2006.1108. .* Geneva: WHO, 2006.

6. Ministry of Health. *Uganda Clinical Guidelines.* Kampala, Uganda: Ministry of Health, 2010.

7. Bhattarai A, Ali AS, Kachur SP, et al.; Impact of Artemisinin-Based Combination Therapy and Insecticide-Treated Nets on Malaria Burden in Zanzibar. *PLOS Medicine* 2007;**4**(11):e309. doi: 10.1371/journal.pmed.0040309.

8. Dondorp AM, Nosten F, Yi P, et al.; Artemisinin resistance in Plasmodium falciparum malaria. *N Engl J Med* 2009;**361**(5):455-67. doi: 10.1056/NEJMoa0808859.

9. Phyo AP, Nkhoma S, Stepniewska K, et al.; Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. *Lancet* 2012;**379**(9830):1960-6. doi: 10.1016/s0140-6736(12)60484-x.

10. Lu F, Culleton R, Zhang M, et al.; Emergence of Indigenous Artemisinin-Resistant Plasmodium falciparum in Africa. *New England Journal of Medicine* 2017;**376**(10):991-993. doi: 10.1056/NEJMc1612765.

11. Umlauf R, Park SJ; Stock-outs! Improvisations and processes of infrastructuring in Uganda's HIV/Aids and malaria programmes. *Glob Public Health* 2018;**13**(3):325-338. doi: 10.1080/17441692.2017.1414287.

12. Wafula FN, Miriti EM, Goodman CA; Examining characteristics, knowledge and regulatory practices of specialized drug shops in Sub-Saharan Africa: a systematic review of the literature. *BMC Health Serv Res* 2012;**12**:223. doi: 10.1186/1472-6963-12-223.

13. Ministry of Health; Uganda Clinical Guidelines. Kampala: Ministry of Health, 2016.

14. Challand S, Willcox M; A clinical trial of the traditional medicine Vernonia amygdalina in the treatment of uncomplicated malaria. *J Altern Complement Med* 2009;**15**(11):1231-7. doi: 10.1089/acm.2009.0098 [doi].

15. World Health Organisation. *WHO Traditional Medicine Strategy 2014-2023.* Geneva: WHO, 2013.

16. Graz B, Diallo D, Falquet J, et al.; Screening of traditional herbal medicine: first, do a retrospective study, with correlation between diverse treatments used and reported patient outcome. *J Ethnopharmacol* 2005;**101**(1-3):338-9.

17. Graz B, Willcox M, Berthe D, et al.; Home treatments alone or mixed with modern treatments for malaria in Finkolo AC, South Mali: reported use, outcomes and changes over 10 years. *Trans R Soc Trop Med Hyg* 2015;**109**(3):209-13. doi: 10.1093/trstmh/tru181.

18. Willcox ML, Graz B, Falquet J, et al.; A "reverse pharmacology" approach for developing an anti-malarial phytomedicine. *Malar J* 2011;**10 Suppl 1**:S8. doi: 10.1186/1475-2875-10-s1-s8.

19. Uganda Bureau of Statistics, ICF International. *Uganda Malaria Indicator Survey 2014-2015: Key Indicators.* Kampala, Uganda, and Rockville, Maryland, USA: UBOS and ICF International., 2015.

20. Nweneka CV, Eneh AU; Malaria parasitaemia in neonates in Port Harcourt, Nigeria. *J Trop Pediatr* 2004;**50**(2):114-6. doi: 10.1093/tropej/50.2.114.

21. Klein Klouwenberg PM, Oyakhirome S, Schwarz NG, et al.; Malaria and asymptomatic parasitaemia in Gabonese infants under the age of 3 months. *Acta Trop* 2005;**95**(2):81-5. doi: 10.1016/j.actatropica.2005.05.003.

22. Royal Botanical Gardens Kew. *The Plant List*. <http://www.theplantlist.org> (Date Accessed 2018 Accessed, date last accessed)

23. Bennet S, Woods T, Liyanage WM, et al.; A simplified general method for cluster-sample surveys of health in developing countries. *World Health Statist. quart.* 1991;**44**:98-106.

24. Kish L. *Survey sampling.* New York: John Wiley, 1965.

25. Sprinthall R. *Basic Statistical Analysis*: Pearson Education, 2011.

26. Diallo D, Graz B, Falquet J, et al.; Malaria treatment in remote areas of Mali: use of modern and traditional medicines, patient outcome. *Trans R Soc Trop Med Hyg* 2006;**100**(6):515-20.

27. Stangeland T, Alele PE, Katuura E, et al.; Plants used to treat malaria in Nyakayojo sub-county, western Uganda. *J Ethnopharmacol* 2011;**137**(1):154-66. doi: 10.1016/j.jep.2011.05.002.

28. Challand S; A survey of the use of medicinal plants and other traditional medicine in Kasese District, Uganda. *Trop Doct* 2005;**35**(4):222-4. doi: 10.1258/004947505774938512 [doi].

29. Kamya MR, Arinaitwe E, Wanzira H, et al.; Malaria transmission, infection, and disease at three sites with varied transmission intensity in Uganda: implications for malaria control. *Am J Trop Med Hyg* 2015;**92**(5):903-12. doi: 10.4269/ajtmh.14-0312.

30. Rasoanaivo P, Wright C, Willcox M, et al.; Whole plant extracts versus single compounds for the treatment of malaria: synergy and positive interactions. *Malaria Journal* 2011;**10**(Suppl 1):S4.

# Tables and Figures

**Table 1**

**Health facilities consulted within first 3 days of illness, and compliance with diagnosis and treatment guidelines (n=722 respondents)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Level of health facility | Number (%) of people who consulted at this level | Number (%) who had a diagnostic test to confirm malaria | No (%) who knew what treatment they had received | Number who received any AL(% of those who knew what treatment they received) | Number (%) who received AL at correct dose (% of those who knew what treatment they received) |
| None (Home treatment) | 16 (2.2%) | NA | 11 (68.8%) | NA | NA |
| Drug Shop*(Informal Health Facility)* | 284 (39.3%) | 26 (9.2%) | 179 (63.0%) | 122 (68.2%) | 54 (30.2%) |
| *Formal Health Facilities:* | 422 (58.5%) | 304 (72.3%) | 285 (67.5%) | 254 (89.1%) | 149 (52.3%) |
| NGO or private clinic | 30 (4.2%) | 16 (53.3%) | 13 (43.3%) | 11 (84.6%) | 5 (38.5%) |
| Health CenterII | 169 (23.4%) | 105 (62.1%) | 64 (37.9%) | 51 (79.7%) | 37 (57.8%) |
| Health CenterIII | 188 (26.0%) | 156 (83.0%) | 182 (96.8%) | 169 (92.9%) | 100 (54.9%) |
| Health CenterIV | 33 (4.6%) | 25 (75.8%) | 24 (72.7%) | 22 (91.7%) | 7 (29.2%) |
| Hospital | 2 (0.3%) | 2 (100%) | 2 (100%) | 1 (50%) | 0 (0%) |
| Total | 722 | 330 (45.7%) | 475 (65.8%) | 376 (79.2%) | 203 (42.7%) |

“NGO or private clinic,” “Health Center II,” “Health Center III,” “Health Center IV,” and “Hospital” are categorized as formal health facilities.

**Table 2**

**Self-reported treatment outcomes by treatment group for those who knew all treatments they received (n=475)**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Treatment taken | Number of patients | Mean duration of illness after treatment (days) | | Self-reported symptom clearance (%) | | | |
| All patients | Patients with positive malaria test | Day 3 | Day 7 | Day 14 | Day 28 |
| AL alone or with herbal | 228 | 7.5 | 8.45 | 21.1 | 74.1 | 90.8 | 98.2 |
| AL+CTX or with herbal | 148 | 8.2 | 8.86 | 25 | 68.2 | 87.8 | 98.6 |
| CTX alone or with herbal | 29 | 8.4 | 8.63 | 10 | 58.6 | 93.1 | 100 |
| CTX + QN or with herbal | 4 | 15.8 | NA | 25 | 25 | 75 | 100 |
| Other antimalarial or with herbal | 18 | 11.3 | 5.5 | 14.3 | 78.6 | 85.7 | 100 |
| Other non-antimalarial or herbal only | 48 | 7.7 | 6.3 | 37.5 | 72.9 | 89.6 | 97.6 |

“Cure rate” defined as becoming afebrile

**Table 3**

**Herbal remedies taken by more than one respondent whose illness started more than seven days before the interview and had complete recollection of treatments taken. Most respondents took more than one herbal medicine simultaneously (n=184)**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Plant species** | **Family** | **Local name (Lusoga)** | **Plant part used** | **Preparation** | **Route of Administration** | **Dose** | **No of patients reporting use** |
| *Vernonia amygdalina* Delile | Asteraceae | Lubirizi | L | Crushed and squeezed into juice | po | 5ml-400ml bd | 161 |
| *Chenopodium opulifolium* Schrad. ex W.D.J.Koch&Ziz. | Amaranthaceae | Namuvu | L | Squeezed into juice | bathing | 200ml added in ½ full basin (about 20l), bd | 31 |
| *Ocimum americanum* L. | Lamiaceae | Kakubansiri | L | Boiled with *Vernonia amygdalina*, *Carica papaya,* and Biyongobera | PO and bathing | 200 mls used for bathing in ½ basin full of water and 1 spoon is taken 3 times a day | 24 |
| *Momordica foetida* Schumach. | Cucurbitaceae | Ebombo | L | Decoction | po | 3 sptds | 19 |
| *Lantana camara* L. | Verbenaceae | Kapanga | L | Decoction of pounded leaves | po | tds | 16 |
| *Azadirachta indica* A.Juss. | Meliaceae | Neem | Fresh L | Decoction | bathing | 200ml added in ½ full basin (about 20l), bd | 13 |
| *Aloe vera* *(*L.) Burm.f. | Xanthorrhoeaceae | Kikaka | L | Decoction | po | 100ml tds | 10 |
| *Hyptis suaveolens* L. | Lamiaceae | Lukowe | L | Squeezed with *Vernonia amygdalina*, *Talinum portulacifolium,* and lusunsuni | bathing | bd | 9 |
| *Cannabis sativum* | Cannabinaceae | Ndhaye | L | Infusion | po | 2 tsp tds | 6 |
| *Carica papaya* L. | Caricaceae | Eipaapali | L | Squeezed with *Vernonia amygdalina*, *Ocimum americanum,* biyongobera | PO and bathing | 2 tsp tds and 200ml added in ½ full basin (about 20l), bd | 6 |
| *Persea americana* Mill. | Lauraceae | Fakedo | L | Squeezed in ¾ basin full of water, and used for bathing, another portion 200mls is taken orally three times a day | PO and bathing |  | 6 |
| *Bidens pilosa* L. | Asteraceae | Bukaala | L | Decoction | po | 5ml tds | 4 |
| *Hibiscus sabdriffa* L*.* | Malvaceae | Ribena | F | Decoction, mixed with squeezed juice of *Vernonia amygdalina* | po | 1 tsp tds | 3 |
| *Psidium guajava* L. | Myrtaceae | Mapera | L | Decoction, with *Ocimum americanum* and *Chenopodium ambrosioides* | bathing | bd | 3 |
| *Lycopersicon esculentum* Mill. | Solanaceae | Naana | L | Decoction | po | 1 tsp tds | 3 |
| *Amaranthus dubius* Mart. ex Thell. | Amaranthaceae | Dodo | L | Squeezed with *Vernonia amygdalina* and *Lantana camara* into juice | bathing |  | 2 |
| *Kedrostis foetidissima* (Jac q.) Cogn. | Cucurbitaceae | Zizi | L | Decoction | po | 100ml tds | 2 |
| *Jatropha curcas* L. | Euphorbiaceae | Kilowa | L | Juice | po | 200ml bd | 2 |
| *Erythrina abyssinica* DC. | Fabaceae | Kiyirigiti | B | Decoction | PO and bathing | 100ml tds po and 100ml in ½ a basin full of water for bathing, three times in a day | 2 |
| *Ocimum gratissimum* L. | Lamiaceae | Mujaja | L | Squeezed with *Chenopodium opulifolium* and *Vernonia amygdalina* | po | 4sp tds | 2 |
| *Moringa oleifera* Lam. | Moringaceae | Moringa | L | Decoction, mixed with *Aloe vera*, *Vernonia amygdalina* | po | 2 sptds | 2 |
| *Talinum portulacifolium*  (Forssk.) Asch. ex Schweinf. | Talinaceae | Mpozia | L | Crushed mixed with warm water | po | 100ml | 2 |

Plant parts: L = Leaf, B = Bark, F = Flower

Route of administration: Po = Oral intake

Frequency: Bds = Twice a day

Tds = Three times a day

Sp = Spoon

**Figure 1**

**Map of Namutumba District and the Study Sites (Marked by Blue Stars)**

